Revenue Sharing Data. During the term of the Contract and continuing thereafter for so long as RECIPIENT has ongoing obligations to the INSTITUTE with respect to revenue sharing pursuant to Attachment D:
Data Sharing. The Parties will exchange information reasonably relevant for regulatory filings for the Licensed Product or otherwise relating to the safety or efficacy of Licensed Products through the coordination meetings described in Section 2.1. In addition, [[Organization A:Organization]] will provide [[Agenus:Organization]] [……] written updates regarding Development activities of the License Products, together with [……] of all relevant [……] (but excluding the [……] and [……] details of [……] created under this Agreement) and [……] data (the “Results”) including as reasonably requested for [[Agenus:Organization]] to meet all applicable regulatory reporting requirements. [[Organization A:Organization]] will maintain all Results in validated computer systems that are compliant with 21 C.F.R. §11. All Results delivered to [[Agenus:Organization]] shall first be de-identified for patient protected information (unless otherwise agreed by the Parties in writing) whether the Clinical Trial is conducted by [[Organization A:Organization]], its Affiliate or a Third Party. In the event of a [……] , [[Organization A:Organization]] shall provide access to all other data related to the Clinical Trial in accordance with procedures set forth in Section 7.2, including [……], [……], [……] and any [……] thereof relevant to any [……]. [[Organization A:Organization]] shall ensure that any agreement it or its Affiliates enters into with any Third Party regarding the Licensed Product or its components shall include data sharing obligations for such Third Party as necessary to permit 36165924.6
Data Sharing. Without limiting the information that Eagle shall provide to TYME hereunder, including, without limitation, the reports deliverable under Section 4.2 hereof, TYME shall provide to Eagle certain information relating to the sale, Commercialization, marketing and promotion of the Product, as may be mutually agreed by the Parties from time to time, for use by Eagle and the Field Force Personnel in connection with the Eagle Activities. The timing of the delivery of such information shall be mutually agreed upon by the Parties, acting reasonably.
Sharing. On a [[Unknown Identifier]] Co-Co Product-by-SYNGAP1 Co-Co Product basis, the Parties shall share all Development Costs for such [[Unknown Identifier]] Co-Co Product equally (50:50), as set forth in Section 9.6.
Sharing. On a [[Unknown Identifier]] Co-Co Product-by-SYNGAP1 Co-Co Product basis, the Parties shall share all Commercialization Costs for such [[Unknown Identifier]] Co-Co Product equally (50:50) in accordance with Section 9.6.
XOMA shall promptly following January 1, 2018, and in any event by March 1, 2018, disclose to and share with, or cause to be disclosed to and shared with, [[AntriaBio:Organization]], all Product Data/Filings and any other technical data Controlled by XOMA and its Affiliates in connection with and specifically relating to the development of the Antibody. [[AntriaBio:Organization]] and its Affiliates and sublicensees shall have the right to use, without additional payment, any and all such Product Data/Filings or other clinical data provided to support any regulatory filings for the Products in accordance with the terms of this Agreement. [[AntriaBio:Organization]] shall reimburse XOMA for its reasonable, documented out-of-pocket costs incurred in connection with such activities.
“Data Sharing Agreements” means those certain data sharing agreements entered into by or on behalf of the Company and a Bottler.
Data Sharing. Arcturus shall, at Providence’s written request, promptly make available to Providence all data generated by Arcturus and its Affiliates or on their behalf under each Statement of Work and allow Providence to inspect and, to the extent necessary or useful for regulatory or intellectual property protection purposes, copy such records. Providence shall maintain all such records and the information contained therein in confidence in accordance with Article 13 hereof and shall not use such records or information except to the extent permitted by this Agreement.
Data Sharing. During , to assist [[FibroGen:Organization]] in conducting thorough due diligence to decide whether to exercise the License Option for such Option Program, HFB will provide all material data and results in the possession of HFB, its Affiliates or subcontractors from non-clinical and pre-clinical studies for Option Compounds that are the subject of each Option Program as soon as reasonably practicable . In addition, , HFB will provide a summary of all material data and results in the possession of HFB, its Affiliates or subcontractors from all non-clinical and pre-clinical studies for Option Compounds for each Option Program. If reasonably requested by [[FibroGen:Organization]], HFB will provide to [[FibroGen:Organization]] and its representatives an in connection with JSC meetings or more frequently as mutually agreed by the Parties.
Data Sharing. The Parties will create a shared data base (the “Data Base”) containing information that may be used by either Party in regard to any Regulatory Filing or Regulatory Approval or for Development or
AllDrafts is a cloud-based editor designed specifically for contracts. With automatic formatting, a massive clause library, smart redaction, and insanely easy templates, it’s a welcome change from Word.
And AllDrafts generates clean Word and PDF files from any draft.